{"schema_version":"secwatch.filing_event.v1","accession":"0001829126-26-000265","form_type":"8-K","ticker":"PMI","cik":"0002030617","company_name":"Picard Medical, Inc.","filed_at":"2026-01-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.044508+00:00","generated_at":"2026-05-16T10:43:50.245958+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Picard Medical publishes investor presentation; expects FDA approval for fully implantable TAH by 2028","bullets":["Over 2,100 STAH implants across 27 countries; only FDA-approved total artificial heart.","Mid-term catalysts: updated BTC label (2Q26), MDR CE-mark (4Q26), NMPA approval (4Q26).","Next-gen fully implantable TAH (Emperor) may seek FDA approval in 2028; patented.","U.S. reimbursement under DRG001 (mean ~$297k); market cap ~$123M as of Jan 11, 2026.","CEO Patrick Schnegelsberg leads team; stock traded $1.63-$13.68 since Aug 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-26-000265","json":"https://secwatch.observer/filing/0001829126-26-000265.json","markdown":"https://secwatch.observer/filing/0001829126-26-000265.md","text":"https://secwatch.observer/filing/0001829126-26-000265.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2030617/000182912626000265/0001829126-26-000265-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2030617/000182912626000265/picardmedical_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T10:43:50.245958+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}